Introduction
Cancer cells evolve during disease progression and in response to treatment (1), influencing their sensitivity to treatment. Circulating tumor cells (CTCs) are considered to be the seeds of metastases (2) and, at the same time, a source of information on tumor tissue that can be acquired through a simple blood sample. Even before a metastatic tumor is clinically evident, it has been reported that a large number of CTCs already exist in the circulation (3, 4) . This provides a more accessible 'liquid biopsy' than tumor tissue biopsies to predict/monitor disease progression and therapy response at both cellular and molecular level. However, current CTC analysis mainly focused on cells expressing epithelial phenotype-specific markers (2) . In fact, activation of epithelial-mesenchymal transition (EMT) is a key process in cancer metastasis (5) and an important factor in promoting invasiveness of cancer cells and their resistance to therapy (6) . Both down-regulation of epithelial markers, such as epithelial cell adhesion molecule (EpCAM), cytokeratin (CK), and E-cadherin, and up-regulation of mesenchymal markers, such as vimentin (VIM), and N-cadherin, have been described (7, 8) .
Hence, CTCs undergoing EMT as part of the metastatic process may be missed when isolated based on their epithelial characteristics only. To address this challenge, we have optimized a novel epitope independent CTC isolation system, Parsortix, to capture CTCs based on the much larger size and less deformability nature of tumor cells compared to normal blood cells (9) . The efficiency of Parsortix in capturing CTCs has been independently validated by other research groups in comparison to CellSearch ® in patients with small cell lung cancer (10) , and other types of cancer including breast, colon and lung (11) . Here we explored its clinical application in prostate cancer prognosis and disease state monitoring.
Prostate cancer is the most common cancer in Western men (12, 13) . Current criteria for risk stratification of newly diagnosed prostate cancer are mainly based on clinical features, including serum prostate specific antigen (PSA), clinical stage, and biopsy/surgical specimen 7 Gleason score (GS) (14) . However, these factors are not sufficient to discriminate between patients with indolent and aggressive disease. Furthermore, when metastatic disease progresses to castration-resistant prostate cancer (CRPC), the established PSA test is not satisfactory for disease prognosis and monitoring. These current clinical unmet needs urge us to identify novel biomarkers that can monitor disease status precisely, accessibly and in real time. Therefore, we investigated the potential of analyzing CTCs with both epithelial and mesenchymal features for cancer prognosis using Parsortix ™ system in prostate cancer as a disease model. We developed a novel technique to perform five rounds of fluorescence in situ hybridization (FISH) on the same slides after immunofluorescence staining. Using this technique, we simultaneously identified the epithelial and mesenchymal cell features and multiple genomic alterations, confirming the malignancy of circulating cells with mesenchymal phenotype. We also demonstrated the correlation of CTCs with advanced disease features. Unexpectedly, we discovered that an increase of circulating megakaryocytes had the trend to be correlated with good prognosis in patients with progressive disease and the combination of CTC and megakaryocyte count may effectively predict survival in advanced disease. 
Materials and Methods

Patients and blood samples
CTC isolation and enumeration
Isolation of CTCs from whole blood using a size-and deformability-based system Parsortix was performed as previously described (9) . Sample harvest and the process of immunostaining are detailed in Supplementary Materials and Methods. Different DAPI+ populations of cells were recorded, including CK+/VIM-/CD45-, CK+/VIM+/CD45-, and CK-/VIM+/CD45-.
FISH after immunofluorescence analysis
Immunofluorescence signals were washed in a stripping buffer (containing 2% SDS, 
Results
Detection of circulating cells with epithelial and mesenchymal features
Using our optimized CTC isolation and detection method (9), we analyzed blood samples from 81 prostate cancer patients ( Table 1 and S1) to identify CK+/VIM-/CD45-, CK+/VIM+/CD45-and CK-/VIM+/CD45-circulating cells (Fig. 1A) . All three types of cells have been detected at high frequencies both in the blood of CRPC and localized cancer patients and they are higher in CRPC patients than those in untreated patients ( FISH on cells after immunofluorescence (Fig. S1 ). In the leucocytes from the healthy donors, the average false positive rates for the probes range from 0.7%-7.1% (Table S2 ).
The multiple FISH technique was then successfully applied to 11 prostate cancer CTC cases for five rounds of FISH (Fig. 1B) and one case for two rounds due to strong florescence background, to investigate the genomic alterations of nine genomic regions, including chromosomal copy number changes and/or rearrangements. In the leucocytes from three randomly selected patients, the average false positive rates for the probes range from 1.5%-7.8% (Table S2) Table S4) .
Association of subgroups of CTCs with serum PSA level, primary biopsy GS and the risk of localized tumor
We further analyzed the relationship of different sub-populations of CTCs to PSA level, primary GS and the risk of localized cancer. While all three sub-populations of CTC numbers were significantly correlated to serum PSA levels (Spearman's ϱ = 0.28, 0.26, and 0.36, and p = 0.01, 0.019 and 0.0009 respectively for CK+/VIM-/CD45-, CK+/VIM+/CD45-and CK-/VIM+/CD45-CTCs), the mesenchymal type had the most significant association ( Fig. 2A) .
As expected, the total number of CTCs had an even more significant correlation (Spearman's ϱ = 0.49, p < 0.0001) due to the greater number of events included for analysis. Due to the multiple tests for analysis, Bonferroni correction test was performed to modify the significant p values. After adjustment, mesenchymal CTC alone but not epithelial and EMTing CTC 13 alone reached statistical significance. Traditional CTCs (combination of epithelial and EMTing CTC) had a significant correlation.
Higher CTC count was also detected in patients with higher GS of primary tumor regardless of therapies received and mesenchymal CTCs had the most significant association (p = 0.001). When total CTCs were included for analysis, a stronger association was observed (p = 0.0001) (Fig. 2B, Table S5 ). After multiple test correction, both epithelial and mesenchymal subtypes of CTCs alone were correlated with higher GS.
When the 38 untreated patients with localized disease were divided into low/intermediate and high risk groups based on NCCN guideline, the number of each subtype of CTCs was higher in high risk group compared to low/intermediate group (Fig. 2C , Table   S5 ). After adjustment for multiple tests, EMTing CTCs and the traditional CTCs (epithelial and EMTing CTCs) still remained statistical significance.
EMTing CTC number was significantly associated with the presence of metastasis
When we correlated the numbers of different sub-populations of CTCs to cancer metastasis, the presence of metastases was significantly associated with higher number of any type of CTCs and the association with EMTing CTCs was most significant (p = 0.0001), which was similar in significance when considering total CTCs (Fig. 2D, Table S5 ). Each subtype of CTCs alone achieved a statistical significance after p value adjustment for multiple tests. (Fig. 2E) . The increased performance of the CRS for metastasis prediction compared to PSA at different sensitivity and specificity level are presented in Table S7 . Box plots of CRS in patients with/without metastasis are shown in Fig.   S2A .
Mesenchymal CTC count is potentially associated with poor survival
Survival analysis was performed in the 40 metastatic CRPC (mCRPC) patients with a median follow-up time of 11.8 months (range 0.7-19.7 months), of which 11 (27.5%) had died.
Median follow-up time for patients still alive at endpoint was 13.3 months (range 4.1-19.7
months). Table 2 
The presence of circulating megakaryocytes was associated with better survival
Unexpectedly, we found a rare population of cells in the harvest samples, with big nuclei (larger than both lymphocytes and most CTCs) of strong DAPI staining, but negative for CK, VIM and CD45 (called BigNeg below) (Fig. 3A) . Due to the strong DAPI staining and larger size of nuclei, such cells were easily identified from other cells with DAPI staining alone 15 ( Fig. 3B) . Through the absence of CK, VIM and CD45 staining, it was possible to exclude
CTCs. FISH analysis for these cells showed 100% polyploidy and most (61.9%) of them had more than ten copies of the genome in each cell (Fig. 3C) , suggesting a special type of cells, distinct to lymphocytes or CTCs. The mean nuclear diameter of BigNeg cells was 17.5 ± 4.9 µm (range: 10 -32 µm), while the mean nuclear diameter for lymphocytes was 6.5 ± 0.8 µm (range: 4 -8 µm). No overlapping in nuclear size was observed between these two categories (Fig. 3D) . (Fig. 4D) . CD45+ lymphocytes, epithelial CTCs, EMTing CTCs, and mesenchymal CTCs were all negative for CD34 and CD41.
Discussion
We have previously shown that CD45 negative cells with both epithelial and mesenchymal features can be detected in prostate cancer patients using Parsortix ™ (9) . Here, we developed a repeated FISH analysis approach following immunofluorescence analysis on the same slide to investigate multiple genomic regions for alterations and, consequently, establish the malignancy of VIM+/CD45-cell populations, which were associated with disease burden and poor prognosis and have the potential to serve as an additional marker to traditional epithelial CTCs for clinical application. As EMT is a critical step for cancer metastasis, analyzing EMT CTCs has great potential for cancer prognosis and progression monitoring (7, 17) . However, based on our experience, it was difficult to achieve complete removal of previous immunofluorescence signals using these pre-treatments and the leftover fluorescence signals often interfered with FISH signal interpretation. Our stripping buffer method, robustly removing immunofluorescence signals completely without damaging cell morphology, facilitates the analysis of multiple genomic alterations on the same cells after immunofluorescence, which increases the chance to detect genomic alterations in most CTCs to confirm their malignancy nature. A panel of genes is better than a single gene or genetic change for cancer prognosis (25) . Multiple genomic region analysis also makes it possible to combine a number of genomic changes for the development of CTC-based genetic prognostic biomarkers. However, in this study, FISH was primarily used to confirm the malignancy of EMT CTCs. We observed a high frequency of alterations in CTCs in the genomic regions investigated, suggesting that extensive genomic alterations occur in CTCs at the stage of 18 cancer metastasis. This is consistent with a previous report that metastatic prostate cancer has more genomic alterations than primary tumor (26) . Our results also showed that genomic heterogeneity exists in prostate cancer CTCs.
In this study, we demonstrated the association of CTC number with GS and the aggressiveness of localized disease, which have not been reported previously. Association of detection of ≥ 5 traditional CellSearch ® isolated CTCs/7.5mL with poor prognosis in patients with advanced prostate cancer was initially reported around a decade ago (27) (28) (29) before an alternative treatment in CRPC patients was better associated with poorer survival than the traditional CK+ CTCs in our cohort, which warrants further investigation. Moreover, mesenchymal CTCs associated with PSA level and GS better than epithelial CTCs and EMTing CTCs were most significantly correlated to cancer metastasis. All these data indicate a potential better prognostic value of mesenchymal than epithelial CTCs in prostate cancer.
As the number of patients in this study is still small, these associations should be validated in large cohorts of samples. EMT has been increasingly recognized for its role in tumor cell invasion, metastatic dissemination and acquisition of therapeutic resistance (6) . Loss of epithelial markers, such as E-cadherin, and gain of mesenchymal markers, such as VIM and N-cadherin, have been proven to be associated with more invasive phenotype or higher GS in prostate cancer cells (34, 35) . EMTing CTCs were most significantly associated with both 19 high-risk localized disease and metastasis, suggesting that these cells under active EMT process are potential indicators for cancer aggressive invasion and metastasis. Taken together, compared to traditional CK+ CTCs, CTCs undergoing or undergone EMT provided more information about disease burden and intrinsic tumor biology.
Radionuclide bone-scan and computed tomography, the current gold standard procedures to detect metastatic sites, are costly, time-consuming and expose patients to radiation. Patients who are unlikely to have metastasis are better off avoiding these costly and potentially harmful procedures. PSA level has been used to predict bone metastases and select patients for bone scans (16) . While our data also showed a strong association between PSA and metastasis and none of the CTC analyses taken alone outperformed PSA for metastatic correlation, a CRS based on both PSA level and EMTing CTC count, significantly improved the metastasis prediction accuracy compared to PSA alone. This suggests that although PSA level correlates with CTC count, they are independent factors contributing to cancer metastasis, potentially by representing different aspects of tumor biology. Large-scale trials are warranted to confirm this superior metastasis prediction model.
The most striking finding is the unexpected discovery of increased circulating megakaryocytes in cancer patients and its association with the survival of CRPC patients. As the nuclei of megakaryocytes are big and with strong DAPI staining, they can be easily identified during CTC analysis. A group of large hyperploid cells with no detectable biomarkers (including epithelial and hepatocellular cancer specific markers) have also been reported recently (36) . As the authors did not include any mesenchymal markers, they considered all these cells as CTCs with EMT. Based on our study, these cells might be a In addition to the bone marrow and the spleen, megakaryocytes have also been detected at very low numbers in circulation (37, 38) . CD34 expresses in hematopoietic stem cells and megakaryocyte progenitor cells, which are all diploidy cells (39) . Its expression can also be seen on mature-appearing megakaryocytes in reactive and disorders of bone marrows (40) .
CD41 is a megakaryocytic lineage specific marker, expressing neither in endothelial cells nor monocytes (39, 41, 42) . The circulating megakaryocytes detected in our study with high DNA content and consistent expression of CD34, represent a specific and potentially abnormal type of megakaryocytes, in which endonuclear DNA replication is active but the CD34 expression is not switched off, hence premature high DNA content megakaryocytes without apparent lobulated nuclei. This is consistent to the finding of CD34 expression in matureappearing megakaryocytes in reactive and disorders of bone marrows (40) and increased ploidization of megakaryocytes have been reported in patients with metastatic tumors (43) .
Platelets, which are released from megakaryocytes in bone marrow has recently been recognized to play an important role in cancer metastasis (44, 45) 
